PMEF
LXRX icon

Point72 Middle East FZE’s Lexicon Pharmaceuticals LXRX Stock Holding History

Point72 Middle East FZE’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,615
Closed -$32.3K – 1711
2023
Q3 		$32.3K Buy
29,615
+990
+3% +$1.74K ﹤0.01% 1278
2023
Q2 		$65.6K Buy
+28,625
New +$76K ﹤0.01% 1265
2023
Q1 		– Sell
-5,167
Closed -$9.87K – 1965
2022
Q4 		$9.87K Buy
+5,167
New +$11K ﹤0.01% 1728

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Point72 Middle East FZE's LXRX Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2023, closing a stake of 29,615 shares — an estimated $32.3K sold.

Point72 Middle East FZE first reported a position in LXRX in Q4 2022 and held it in 3 quarters. The position peaked at $65.6K in Q2 2023. 106 funds tracked by Wall St. Rank hold LXRX as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Lexicon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 29,615 Lexicon Pharmaceuticals shares in Q4 2023, an estimated $32.3K.
  • Point72 Middle East FZE first reported a position in Lexicon Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Point72 Middle East FZE's Lexicon Pharmaceuticals position peaked at $65.6K in Q2 2023.
  • 106 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.